Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response
Abstract Adoptive T cell therapy with T cell receptor (TCR)-modified T cells has shown promise in treating metastatic melanoma and other malignancies. However, studies are needed to improve the efficacy and durability of responses of TCR-modified T cells. Standard protocols for generating TCR-modifi...
Guardado en:
Autores principales: | Siao-Yi Wang, Tamson V. Moore, Annika V. Dalheim, Gina M. Scurti, Michael I. Nishimura |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0d6455e91542435a9f8f3cd3c71292a6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy
por: Ali R. Jazirehi
Publicado: (2021) -
Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody
por: Saeed M, et al.
Publicado: (2016) -
Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2
por: Kanako Shimizu, et al.
Publicado: (2021) -
NetTCR-2.0 enables accurate prediction of TCR-peptide binding by using paired TCRα and β sequence data
por: Alessandro Montemurro, et al.
Publicado: (2021) -
Obtaining the retainer for waterproofing road bitumens
por: Evgeniy V. Boev
Publicado: (2021)